The ferroptosis-related tumor drug discovery system independently developed by Creative Biolabs includes three modules: intelligent computing, automated experiments, and expert experience, exploring a broader chemical space with higher efficiency and lower cost, greatly reducing the number of wet experiments, and accelerating the DMTA cycle of drug discovery.

Introduction to Small Molecules Ferroptosis-based Cancer Therapy

Tumor cells exhibit elevated metabolic levels and iron content, rendering them more susceptible to iron-induced cell death. Iron-mediated cell death plays a pivotal role in the initiation and progression of tumors. Currently, numerous small molecule compounds have been utilized as inducers of iron-induced cell death in tumor cells or inhibitors in immune cells to achieve superior anti-tumor effects.

As a specialized CRO company focusing on research targeting ferroptosis-induced tumor cell death, Creative Biolabs has established a series of services for the development and validation of small molecules targeting GSH-GPX4, iron-related proteins, p53, and VDAC involved in iron-induced cell death as well as immune cells, aiming to provide a critical foundation for the research and development of novel drugs targeting tumor iron-induced cell death.

Fig.1 Ferroptosis-Inducing Chemical Probes And Drug Candidates.¹

Small Molecules-induced Ferroptosis Solutions

Small molecules-induced ferroptosis has a strong inhibitory effect on tumor growth and can enhance the sensitivity of chemotherapy drugs. The use of small molecule compounds to regulate ferroptosis to intervene in the occurrence and development of related tumors has become a hot spot and focus of research and treatment.

The small-molecule compounds introduced by us have the advantages of small size, easier to enter the central nervous system through the blood-brain barrier, and more direct action on cancer cells, so they have been widely recognized and welcomed by customers. For the convenience of our worldwide users engaged in cancer ferroptosis research, we provide more than 30 kinds of active small molecules targeting tumor ferroptosis, hoping to speed up your scientific research project.

Our small molecules targeting ferroptosis have a low production cost, and minimal burden, and require low production, transportation, storage conditions, and technical requirements. They can be utilized for high-throughput and high-content screening, making it a powerful tool for cancer immunotherapy research.

Featured Services

1. Antitumor small molecule discovery

Small molecules engineered from natural product skeletons have become common targets for ferroptosis-based cancer therapy. In Creative Biolabs, our staff can provide chemical diversity modification, synthesize a variety of small molecule compounds with different modifications, and verify killing activity in anti-tumor phenotype preliminary screening.

2. Anti-tumor small molecule target identification

To further elucidate the anti-tumor mechanism of this new skeleton molecule, we will provide screening analysis of small molecule-induced cell morphology, cell death, and other mechanisms in various cell lines of different cancer models.

Advantages

• Diverse target selection includes GLUT1, GLUT4, TIGAR,GLS2, SCO2,SLC7A11, RRAD, SAT1,p21, G6PDH, DPP4, and SOSC1;
• Detailed instruction manual, compound structure, target information, activity description;
• NMR, HPLC/LCMS, and other detection techniques ensure the correct structure, high purity, and reduction of false positives;

Creative Biolabs as an experienced bio-company, can provide a rich variety of ferroptosis-related small molecule services. We use our many successful experiences to guide your oncology development program while streamlining handovers, reducing errors, avoiding rework, and reducing costs. If you are interested in our services, please contact us or send us an inquiry.

Reference

1. Koeberle, Solveigh C., et al. "Ferroptosis-modulating small molecules for targeting drug-resistant cancer: Challenges and opportunities in manipulating redox signaling." Medicinal Research Reviews 43.3 (2023): 614-682.

For Research Use Only | Not For Clinical Use